Skip to Content
Søg Menu
Velkommen til lungecancer

Få de seneste artikler og MEDtalks om lungecancer

Seneste nyt om lungecancer

Behov for mere viden om behandling af NSCLC med immunterapi uden driver mutationer

  • / Julie Stougaard / Jan Andreasen
Michael Stenger

WCLC 2025: Lung Cancer Screening and Early Results from the Danish PLUS Trial

/ Michael Stenger
WCLC25Lungecancer Play the Video
Maria Silvoniemi

Clinical Dilemmas in the Management of NSCLC Without Driver Mutations

/ Maria Silvoniemi
NSCLCLungecancer Play the Video
Edyta Maria Urbanska

Behandling af patienter med lungecancer og positiv for NTRK-fusioner

/ Edyta Maria Urbanska
Lungecancer Play the Video

Lung cancer Highlights

Lung Cancer Insights: What’s New in the Field

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Nyt behandlingsgennembrud for EGFR-muteret lungekræft

/ Seppo W. Langer
NSCLCLungecancer

New Data Support Osimertinib as a Backbone Treatment for EGFRm Advanced NSCLC

/ Jan Andreasen
WCLC25NSCLCLungecancer
Hent flere

Artikler

Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: PALOMA-2 Update

/ Jan Andreasen
WCLC25NSCLCLungecancer

First-Line NSCLC Without Driver Mutations: Practice, Gaps, and Costs

/ Ronny Öhman / Jan Andreasen
NSCLCLungecancer

Jens Benns møde med Heine var skelsættende for valget af lungeonkologien

/ Jens Benn Sørensen / Amanda Feldballe Bernholm
Lungecancer

Lazertinib + Amivantamab: A New Chemotherapy-Free Option for EGFR-Mutated Advanced NSCLC

/ Antonio Passaro / Jan Andreasen
Lungecancer

Thoraxpatologien er en aktiv faktor i behandlingen af lungecancer

/ Eric Santoni Rugiu / Amanda Feldballe Bernholm
Lungecancer

Eric Santoni-Rugiu: Vejen fra leverpatologi til nyudnævnt professor i thorakal patologi 

/ Eric Santoni Rugiu / Jan Andreasen
Lungecancer

WCLC I Kongresside

6.-9. september 2025

Se mere

MEDtalks

Luis Paz-Ares

ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

/ Luis Paz-Ares
ASCO25Lungecancer Play the Video
Odd Terje Brustugun

Perspektiver på behandlingsvalg ved NSCLC uten drivermutasjoner

/ Odd Terje Brustugun
Lungecancer Play the Video
Edyta Maria Urbanska

Amivantamab + lazartinib i 1.-linje øger overlevelsen ved avanceret EGFR muteret NSCLC vs osimertinib

/ Edyta Maria Urbanska
Lungecancer Play the Video
Miriam Grønberg

Treatment Timing Impacts Survival in Limited Stage Small Cell Lung Cancer

/ Miriam Grønberg
Lungecancer Play the Video
Nicolas Girard

Prophylactic Treatment Lowers Skin Toxicity in NSCLC Patients on Amivantamab + Lazertinib

/ Nicolas Girard
Lungecancer Play the Video
Bjørn Henning Grønberg

Norge har indført 1. valg af lorlatinib til patienter med avanceret ALK-positiv NSCLC på baggrund af flotte PFS data

/ Bjørn Henning Grønberg
Lungecancer Play the Video
Hent flere
Back to top